Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

Journal of Neurology

Volumn 259, Issue 11, 2012, Pages 2293-2298

  Outteryck, Olivier ^a   Ongagna, Jean Claude ^b   Duhamel, Alain ^c   Zéphir, Hélène ^a   Collongues, Nicolas ^b   Lacour, Arnaud ^a   Fleury, Marie Céline ^b   Berteloot, Anne Sophie ^a   Blanc, Frédéric ^b   Giroux, Marianne ^a   Vermersch, Patrick ^a   De Sèze, Jérôme ^b  

^a UNIV LILLE   (France)

^b HÔPITAL CIVIL   (France)

^c Faculté de Médecine Pôle Recherché   (France)

Author keywords

JCV; Multiple sclerosis; Natalizumab; Progressive multiple leukoencephalopathy

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; JC VIRUS ANTIBODY; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; FRANCE; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; YOUNG ADULT;

EID: 84868207726     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6487-5     Document Type: Article

References (15)

1. Sandrock A, Hotermans C, Richman S et al (2011) Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: Role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status [Poster AAN 2011]. P03.248
2. Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 68:295-303
3. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387 (Pubitemid 26072233)
4. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093-2109 (Pubitemid 23066842)
5. Warnke C, Dehmel T, Posevitz-Fejfàr A et al (2011) Anti-JCV antibody prevalence in a german MS cohort [abstract]. Mult Scler 10(suppl):P520
6. Olsson T, Achiron A, Alfredsson L et al (2011) Prevalence of anti JCV antibodies in a multi-national cohort of multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P338
7. Bozic C, Richman S, Plavina T et al (2011) Anti-John Cunnig-ham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742-750
8. Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of poly-omavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:836-846
9. Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067-1074
10. Rudick RA, O'Connor PW, Polman CH et al (2009) Assessment of JC Virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304-310
11. Bozic C, Subramanyam M, Paes D et al (2011) JCV epidemiology in MS: epidemiology on anti-JC virus antibody prevalence in multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P801
12. Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalop-athy. Neurology 76:1697-1704
13. Phan-Ba R, Lommers E, Tshibanda L (2011) MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83:284-286
14. Kappos L, Bates D, Edan G et al (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745-758
15. Sorensen PS, Bertolotto A, Edan G et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mutl Scler 18:143-152